Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

207.2 -1.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

206.5

Massimo

211.7

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

76.126

27.305

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+21.67% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-97M

20B

Apertura precedente

208.25

Chiusura precedente

207.2

Notizie sul Sentiment di mercato

By Acuity

26%

74%

70 / 493 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2026, 21:55 UTC

Utili

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 gen 2026, 23:52 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 gen 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 gen 2026, 23:40 UTC

Discorsi di Mercato

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 gen 2026, 22:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 gen 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 gen 2026, 21:44 UTC

Utili

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 gen 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 gen 2026, 21:30 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One To Acquire Brex >COF

22 gen 2026, 21:13 UTC

Utili

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 gen 2026, 21:10 UTC

Utili

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 gen 2026, 21:06 UTC

Utili

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Rev $15.58B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q EPS $3.26 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Interest Margin 8.26% >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net $2.13B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Adj EPS $3.86 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Charge-Offs $3.8B >COF

22 gen 2026, 21:05 UTC

Utili

Intuitive Surgical 4Q EPS $2.21 >ISRG

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

21.67% in crescita

Previsioni per 12 mesi

Media 248.2 EUR  21.67%

Alto 260 EUR

Basso 240 EUR

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

3

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

70 / 493 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat